1
|
Zhang XR, Chien PN, Nam SY and Heo CY:
Anaplastic large cell lymphoma: Molecular pathogenesis and
treatment. Cancers (Basel). 14:16502022. View Article : Google Scholar : PubMed/NCBI
|
2
|
Leventaki V, Bhattacharyya S and Lim MS:
Pathology and genetics of anaplastic large cell lymphoma. Semin
Diagn Pathol. 37:57–71. 2020. View Article : Google Scholar : PubMed/NCBI
|
3
|
Kaseb H, Mukkamalla SKR and Rajasurya V:
Anaplastic large cell lymphoma. StatPearls Treasure Island (FL):
2022
|
4
|
Savage KJ, Harris NL, Vose JM, Ullrich F,
Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne
RD, et al: ALK-anaplastic large-cell lymphoma is clinically and
immunophenotypically different from both ALK+ ALCL and peripheral
T-cell lymphoma, not otherwise specified: report from the
international peripheral T-cell lymphoma project. Blood.
111:5496–5504. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Sibon D, Nguyen DP, Schmitz N, Suzuki R,
Feldman AL, Gressin R, Lamant L, Weisenburger DD, Rosenwald A,
Nakamura S, et al: ALK-positive anaplastic large-cell lymphoma in
adults: An individual patient data pooled analysis of 263 patients.
Haematologica. 104:e562–e565. 2019. View Article : Google Scholar : PubMed/NCBI
|
6
|
Morel A, Brière J, Lamant L, Loschi M,
Haioun C, Delarue R, Tournilhac O, Bachy E, Sonet A, Amorim S, et
al: Long-term outcomes of adults with first-relapsed/refractory
systemic anaplastic large-cell lymphoma in the pre-brentuximab
vedotin era: A LYSA/SFGM-TC study. Eur J Cancer. 83:146–153. 2017.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Wang QQ, Jiang Y and Naranmandura H:
Therapeutic strategy of arsenic trioxide in the fight against
cancers and other diseases. Metallomics. 12:326–336. 2020.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Wahiduzzaman M, Ota A and Hosokawa Y:
Novel mechanistic insights into the anti-cancer mode of arsenic
trioxide. Curr Cancer Drug Targets. 20:115–129. 2020. View Article : Google Scholar : PubMed/NCBI
|
9
|
Li Z, Chen Q, Zhang W, Si G, Li J, Jiao D
and Han X: Efficacy and safety of the arsenic trioxide/lipiodol
emulsion in the transcatheter arterial chemoembolization combined
with apatinib in the treatment of advanced hepatocellular
carcinoma. Can J Gastroenterol Hepatol. 2021:55657932021.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Zhang Y, Pan D, Yang H, Huang J, He Z, Li
H and Li D: Effects of arsenic trioxide combined with platinum
drugs in treatment of cervical cancer: A protocol for systematic
review and meta-analysis of randomized controlled trials. Medicine
(Baltimore). 99:e229502020. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kutny MA, Alonzo TA, Abla O, Rajpurkar M,
Gerbing RB, Wang YC, Hirsch BA, Raimondi S, Kahwash S, Hardy KK, et
al: Assessment of arsenic trioxide and all-trans retinoic acid for
the treatment of pediatric acute promyelocytic leukemia: A report
from the children's oncology group AAML1331 trial. JAMA Oncol.
8:79–87. 2022. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhong L, Xu F and Chen F: Arsenic trioxide
induces the apoptosis and decreases NF-κB expression in lymphoma
cell lines. Oncol Lett. 16:6267–6274. 2018.PubMed/NCBI
|
13
|
Li XY, Li Y, Zhang L, Liu X, Feng L and
Wang X: The antitumor effects of arsenic trioxide in mantle cell
lymphoma via targeting Wnt/β-catenin pathway and DNA
methyltransferase-1. Oncol Rep. 38:3114–3120. 2017. View Article : Google Scholar : PubMed/NCBI
|
14
|
Li HM, Long Y, Qing C, Yu M, Li ZH, Zhang
XM, Li XJ, Chen YJ, Zhang YL and Liang Y: Arsenic trioxide induces
apoptosis of Burkitt lymphoma cell lines through multiple apoptotic
pathways and triggers antiangiogenesis. Oncol Res. 19:149–163.
2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Li CL, Wei HL, Chen J, Wang B, Xie B, Fan
LL and Li LJ: Arsenic trioxide induces autophagy and antitumor
effects in Burkitt's lymphoma Raji cells. Oncol Rep. 32:1557–1563.
2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kouhpaikar H, Sadeghian MH, Rafatpanah H,
Kazemi M, Iranshahi M, Delbari Z, Khodadadi F, Ayatollahi H and
Rassouli FB: Synergy between parthenolide and arsenic trioxide in
adult T-cell leukemia/lymphoma cells in vitro. Iran J Basic Med
Sci. 23:616–622. 2020.PubMed/NCBI
|
17
|
Yue LM, Chau D, Kwong YL and Tse E:
Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive
diffuse large B-cell lymphoma through targeting ALK-fusion
oncoprotein. Br J Haematol. 194:1085–1090. 2021. View Article : Google Scholar : PubMed/NCBI
|
18
|
Piao W, Chau D, Yue LM, Kwong YL and Tse
E: Arsenic trioxide degrades NPM-ALK fusion protein and inhibits
growth of ALK-positive anaplastic large cell lymphoma. Leukemia.
31:522–526. 2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Park SH, Kim S, Ko OB, Koo JE, Lee D,
Jeong YP, Huh J, Kim SB, Kim SW, Lee JL and Suh C: ESHAP salvage
therapy for refractory and relapsed non-Hodgkin's lymphoma: A
single center experience. Korean J Intern Med. 21:159–164. 2006.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Kchour G, Tarhini M, Kooshyar MM, El Hajj
H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah
H, et al: Phase 2 study of the efficacy and safety of the
combination of arsenic trioxide, interferon alpha, and zidovudine
in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
Blood. 113:6528–6532. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne
RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca
E, et al: Revised response criteria for malignant lymphoma. J Clin
Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhu HH, Hu J, Lo-Coco F and Jin J: The
simpler, the better: Oral arsenic for acute promyelocytic leukemia.
Blood. 134:597–605. 2019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zhao H, Sun G, Kong D, Zhang Y, Shi W,
Zhao M, Hong L and Qiao Z: A phase II study of arsenic trioxide in
patients with relapsed or refractory malignant lymphoma. Med Oncol.
32:792015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Hermine O, Dombret H, Poupon J, Arnulf B,
Lefrère F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC,
et al: Phase II trial of arsenic trioxide and alpha interferon in
patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Hematol J. 5:130–134. 2004. View Article : Google Scholar : PubMed/NCBI
|
25
|
Marçais A, Cook L, Witkover A, Asnafi V,
Avettand-Fenoel V, Delarue R, Cheminant M, Sibon D, Frenzel L, de
Thé H, et al: Arsenic trioxide (As2O3) as a
maintenance therapy for adult T cell leukemia/lymphoma.
Retrovirology. 17:52020. View Article : Google Scholar : PubMed/NCBI
|
26
|
Tang J, Yao C, Liu Y, Yuan J, Wu L, Hosoi
K, Yu S, Huang C, Wei H and Chen G: Arsenic trioxide induces
expression of BCL-2 expression via NF-κB and p38 MAPK signaling
pathways in BEAS-2B cells during apoptosis. Ecotoxicol Environ Saf.
222:1125312021. View Article : Google Scholar : PubMed/NCBI
|
27
|
Daugrois C, Bessiere C, Dejean S,
Anton-Leberre V, Commes T, Pyronnet S, Brousset P, Espinos E,
Brugiere L, Meggetto F and Lamant L: Gene expression signature
associated with clinical outcome in ALK-positive anaplastic large
cell lymphoma. Cancers (Basel). 13:55232021. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chen MT, Fu XH, Huang H, Wang Z, Fang XJ,
Yao YY, Ren QG, Chen ZG and Lin TY: Combination of crizotinib and
chemotherapy in patients with relapsed or refractory anaplastic
lymphoma kinase (ALK)-positive anaplastic large cell lymphoma
(ALCL). Leuk Lymphoma. 62:571–580. 2021. View Article : Google Scholar : PubMed/NCBI
|
29
|
Peng X, Xiong X, Li Y, Feng C, Liu H, Wu
P, Li C and Weng W: Encouraging early outcomes of treatment with
arsenic trioxide combined with chemotherapy for alveolar
rhabdomyosarcoma in children: 4 Case reports. Front Oncol.
11:7516232021. View Article : Google Scholar : PubMed/NCBI
|